BioSpace News Archive

Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an investment commitment of up to US$20 million from Canada Pension Plan Investment Board (CPPIB).

Up to 44-Week Data Shows Significant Improvement in Both Obstacle Awareness and Object Detection

HistoSonics, developer of a novel non-invasive sonic beam therapy platform, was named by The Observer as the one of the nation’s most influential healthcare companies during the 38th J.P. Morgan Healthcare Investment Conference in San Francisco, CA.

Dr. Eric Mayer, a board certified urologist specializing in minimally invasive urologic procedures using the da Vinci surgical system, has joined Capital Health as director of Urologic Robotic Surgery.

Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year, non-exclusive collaboration agreement to broaden the adoption of distributable next-generation sequencing-based (NGS) testing in oncology

Ripretinib Marketing Applications Submitted to Health Canada and Australia’s Therapeutic Goods Administration for Patients with Advanced GIST via the U.S. FDA’s Project Orbis Pilot Program

Mentice AB, a world leader in simulation solutions for endovascular therapies, will be showcasing the first of-its-kind flexible Coronary Essentials training solution at the 20th International Meeting on Simulation in Healthcare in San Diego from January 19 to January 22.

Orlando Health will deploy ThinkAndor™, Andor Health’s mobile communication technology, to enable comprehensive, real-time care team collaboration beyond the walls of its enterprise.

Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Group”), a global leader in the application of gene editing and gene modulation technologies, has announced that it has signed a collaboration and license agreement with Mammoth Biosciences (“Mammoth” or the “Company”), to access Mammoth’s novel CRISPR platform and thereby facilitate delivery of a new generation of genetically engineered CHO cells for the production of biotherapeutics such as therapeutic antibodies.

Median Technologies (Paris:ALMDT), The Imaging Phenomics Company® today announced its preliminary full year 2019 unaudited financial results.